These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38505844)

  • 1. Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Mar; 15(3):342-343. PubMed ID: 38505844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
    Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
    Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.
    Fan M; Hu L; Shi S; Song X; He H; Qi B
    Bioorg Med Chem; 2023 Dec; 96():117534. PubMed ID: 37952262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):773-774. PubMed ID: 38894899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
    Obst-Sander U; Ricci A; Kuhn B; Friess T; Koldewey P; Kuglstatter A; Hewings D; Goergler A; Steiner S; Rueher D; Imhoff MP; Raschetti N; Marty HP; Dietzig A; Rynn C; Ehler A; Burger D; Kornacker M; Schaffland JP; Herting F; Pao W; Bischoff JR; Martoglio B; Alice Nagel Y; Jaeschke G
    J Med Chem; 2022 Oct; 65(19):13052-13073. PubMed ID: 36178776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
    Mittal L; Tonk RK; Awasthi A; Asthana S
    Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.
    Li M; Guo J
    ACS Chem Neurosci; 2021 Feb; 12(3):462-472. PubMed ID: 33435671
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
    J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.
    Bhanja KK; Sharma M; Patra N
    J Phys Chem B; 2023 Dec; 127(50):10749-10765. PubMed ID: 38055900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
    Wittlinger F; Heppner DE; To C; Günther M; Shin BH; Rana JK; Schmoker AM; Beyett TS; Berger LM; Berger BT; Bauer N; Vasta JD; Corona CR; Robers MB; Knapp S; Jänne PA; Eck MJ; Laufer SA
    J Med Chem; 2022 Jan; 65(2):1370-1383. PubMed ID: 34668706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
    Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
    Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Compounds as TEAD Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Sep; 14(9):1152-1153. PubMed ID: 37736181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma.
    Tripathi SK; Biswal BK
    Drug Discov Today; 2021 Jun; 26(6):1466-1472. PubMed ID: 33581322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
    Wan S; Yan R; Jiang Y; Li Z; Zhang J; Wu X
    J Biomol Struct Dyn; 2019 Oct; 37(16):4384-4394. PubMed ID: 30499387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Oct; 14(10):1334-1335. PubMed ID: 37849539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1045-1046. PubMed ID: 37583830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 May; 14(5):555-556. PubMed ID: 37197476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jun; 14(6):707-708. PubMed ID: 37312857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):775-776. PubMed ID: 38894910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.